Antihypertensive agents

Antihypertensive agents has been studied in 276 papers since 1975: 6 trials and 170 observational studies in people, 1 in animals, 92 reviews; 98 in the past year. The newest story, Oct 4, 2026: “Frailty accelerates before and after hypertension diagnosis”.

Intervention

276 papers study it114 findingsUpdated

MeSH

4 new papers in 30 daysSee all 276 papers on antihypertensive agents

At a glance

Antihypertensive agents reduce cardiovascular disease and mortality in human studies, with independent labs reporting these outcomes again. Cognitive results vary, and a trial reports higher dependency or death in participants with baseline systolic pressure of 160–179 mmHg. Some papers declare company ties, including Novartis and Sanofi.

114 findings in 85 papers from 1975 to 2026, 12 of them since April 2026

Independent labs found the same change in people. 59 independent labs in 25 countries.

“During the follow-up, the incidence of adverse events such as stroke recurrence and major vascular events did not differ significantly between early and delayed treatment groups in any subgroup.”
Initial systolic blood pressure, antihypertensive treatment timing and outcomes in acute ischemic stroke: a subgroup analysis of CATIS-2 trialJournal of hypertension2026doi:10.1097/hjh.0000000000004303

8 of its findings point the other way.

Humans: replicated by independent labs. Mice: a single group. Cells and worms or flies: nothing yet.
  • 59 independent labs in 25 countries
  • 8 findings against
  • Funders: National Institutes of Health and others
  • 7 of 93 findings with company ties
  • Human trial6
  • Humans170
  • Animals1
  • In silico3

Studies in people

5 studies gave antihypertensive agents to people and measured what changed.

What changedDesignPeopleSource

up: Improves cognitive functionSMD 0.06 (95% CI 0.03-0.09)

Review of trials2.0-3.9 years16,823 people pooledolder adultsOlder adults; in hypertensive older adultsJournal of the American Medical Directors Association, Apr 11, 2026

up: Raises the risk of functional dependency or death13.3% vs. 10.4%; OR 1.32, 95% CI 1.00–1.76

no change: Has no effect on stroke recurrence

Randomized trial90 days4,802 people65.0% were malemean age 63.7 yearsAIS patientsJournal of hypertension, Mar 18, 2026

down: Decreases blood pressure<140/90 mmHg

down: Decreases muscle sympathetic nerve trafficP<0.001

down: Decreases norepinephrineP<0.001

Trial3 monthsPatient cohortsHigh blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, Mar 18, 2026

down: Protects against cardiovascular diseaseP for interaction >0.05 for all outcomes

Randomized trialmedian follow-up period of 4.4 years4,692 peopleBothmean age, 72.1 yearsOlder adults; in individuals with isolated systolic hypertensionHypertension (Dallas, Tex. : 1979), Jan 14, 2025

down: Decreases retinal arteriolar wall-to-lumen ratio-6.0 ± 8.0%

no change: Has no effect on retinal arteriolar wall-to-lumen ratio

Treated cohort1,000 peopleGeneral population; short-term drug-induced blood pressure drop (-29.3 ± 17.3/-14.4 ± 10.0 mmHg)Journal of hypertension, Apr 12, 2016

What did studies of antihypertensive agents find?

47

Studies of antihypertensive agents measured 47 outcomes; the most studied are cardiovascular disease (5 studies), cognitive function (3) and mortality (3).

Cardiovascular disease

downin humans5RR 0.72

5 studies
  1. Antihypertensive agents protect against cardiovascular disease in individuals with isolated systolic hypertension (P for interaction >0.05 for all outcomes).

    “there was no evidence of an interaction between baseline FI and antihypertensive treatment (P for interaction >0.05 for all outcomes).”

    Human trialin individuals with isolated systolic hypertensionn = 4,692

    Impact of Frailty on Antihypertensive Treatment in Older Adults

    Hypertension (Dallas, Tex. : 1979)

  2. Antihypertensive agents protect against cardiovascular disease in humans (genetically proxied).

    “There is strong evidence supporting the protective effects of genetically proxied antihypertensive drugs on cardiovascular diseases.”

    Reviewgenetically proxied

    Systematic review of Mendelian randomization studies on antihypertensive drugs

    BMC medicine

  3. Antihypertensive agents protect against cardiovascular disease in humans (hypertension).

    “pooled analyses suggest that intensive BP lowering provides greater cardiovascular protection than less intensive strategies in elderly hypertensive patients”

    Reviewhypertension

    Treatment of hypertension in the elderly: target the lowest well-tolerated blood pressure

    Expert review of cardiovascular therapy

  4. Antihypertensive agents decrease cardiovascular disease in humans (moderate to severe hypertension) (RR 0.72 (0.68, 0.77)).

    “Treatment also reduced total cardiovascular morbidity and mortality, RR 0.72 (0.68, 0.77); event rates per 1000 participants reduced from 149 to 106.”

    Reviewmoderate to severe hypertensionmean 4.5 yearsn = 24,055

    Pharmacotherapy for hypertension in the elderly

    The Cochrane database of systematic reviews

  5. Antihypertensive agents prevent cardiovascular disease in humans (hypertensive) (NNT 18 (95% CI, 14 to 25)).

    “Only 18 subjects (95% CI, 14 to 25) needed to be treated to prevent one cardiovascular event (cerebrovascular or cardiac).”

    Reviewhypertensive5 years

    Hypertension in the elderly. Implications and generalizability of randomized trials

    JAMA

More on Cardiovascular disease

Cognitive function

upin humans3

3 studies
  1. Antihypertensive agents improve cognitive function in hypertensive older adults (SMD 0.06 (95% CI 0.03-0.09)).

    “Antihypertensive treatment significantly improved cognitive function scores (SMD, 0.06; 95% CI, 0.03-0.09; P < .001, GRADE moderate certainty)”

    Human trialin hypertensive older adults2.0-3.9 yearsn = 16,823

    Impact of Different Antihypertensive Drug Classes on Incident Dementia in Older Adults: A Systematic Review and Meta-Analysis

    Journal of the American Medical Directors Association

  2. Antihypertensive agents are linked with better cognitive function in humans (hypertension) (26 (25 - 27) vs 24 (22 - 25)).

    “The median (IQR) MoCA score (out of 30 points) in patients taking antihypertensives was 26 (25 - 27), while it was 24 (22 - 25) in the control group.”

    Humanshypertensionn = 210

    Antihypertensive therapy is associated with improved visuospatial, executive, attention, abstraction, memory, and recall scores on the montreal cognitive assessment in geriatric hypertensive patients

    Cerebral circulation - cognition and behavior

  3. Antihypertensive agents improve cognitive function in humans (blood pressure reduction).

    “clinical trials have been overall favorable in improving cognition by reductions in blood pressure using antihypertensive agents.”

    Reviewblood pressure reduction

    Effects of Hypertension on Alzheimer's Disease and Related Disorders

    Current hypertension reports

Mortality

downin humans3RR 0.9

3 studies
  1. Antihypertensive agents decrease mortality in humans.

    “Medical treatment of hypertension reduces cardiovascular morbidity and mortality in the elderly”

    Review

    Management of hypertension in the elderly

    Nature reviews. Cardiology

  2. Antihypertensive agents decrease mortality in humans (moderate to severe hypertension) (RR 0.90 (0.84, 0.97)).

    “Treatment reduced total mortality, RR 0.90 (0.84, 0.97); event rates per 1000 participants reduced from 116 to 104.”

    Reviewmoderate to severe hypertensionmean 4.5 yearsn = 24,055

    Pharmacotherapy for hypertension in the elderly

    The Cochrane database of systematic reviews

  3. Antihypertensive agents decrease mortality in humans (hypertensive) (NNT 78 (95% CI, 50 to 180)).

    “78 older subjects (95% CI, 50 to 180) needed to be treated to prevent a fatal cardiac event.”

    Reviewhypertensive5 years

    Hypertension in the elderly. Implications and generalizability of randomized trials

    JAMA

Blood pressure

downin humans2

2 studies
  1. Antihypertensive agents decrease blood pressure in humans (<140/90 mmHg).

    “antihypertensive drug treatment lowered clinic blood pressure to values <140/90 mmHg”

    Human trial3 months

    Lack of regional and whole body sympathetic normalization during antihypertensive drug treatment: a potential link for the residual risk

    High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension

  2. Antihypertensive agents decrease blood pressure in humans (hypertension).

    “all antihypertensive agents will lower blood pressure”

    Reviewhypertension

    Challenges in the Management of Hypertension in Older Populations

    Advances in experimental medicine and biology

Dementia

no changein humans2HR 0.84

2 studies
  1. Antihypertensive agents were not clearly linked with dementia in humans (baseline hypertension) (HR 0.84, 95%CI 0.70-1.02, p=0.08).

    “Overall, 'any' AHM use was not associated with lower incident dementia risk, compared with untreated participants (HR 0.84, 95%CI 0.70-1.02, p=0.08)”

    Humansbaseline hypertensionn = 13,916

    Antihypertensive medications and dementia in older adults with hypertension

    medRxiv : the preprint server for health sciencesPreprint

  2. Antihypertensive agents were not clearly linked with dementia in humans (hypertension).

    “Baseline treatment was not associated with the risk of incident dementia.”

    Humanshypertension3.02±0.82 yearsn = 776

    Antihypertensive Medication Class and the Risk of Dementia and Cognitive Decline in Older Adults: A Secondary Analysis of the Prospective HELIAD Cohort

    Journal of Alzheimer's disease : JAD

More on Dementia

Cardiovascular mortality

downin humans2

2 studies
  1. Antihypertensive agents decrease cardiovascular mortality in humans (hypertension).

    “Pharmacotherapy of hypertension in elderly is in vast majority of subjects highly beneficial with decrease of cardiovascular (CV) events and CV mortality.”

    Reviewhypertension

    Therapy of hypertension in elderly population and its potential risks

    Vnitrni lekarstvi

  2. Antihypertensive agents decrease cardiovascular mortality in humans (hypertension) (from 69 to 50 deaths per 1000 participants (95% CI of the difference 9 to 31)).

    “Cardiovascular mortality was reduced from 69 to 50 deaths (95% CI of the difference 9 to 31).”

    Reviewhypertensionapproximately 5 yearsn = 21,908

    Pharmacotherapy for hypertension in the elderly

    The Cochrane database of systematic reviews

Blood pressure

upin humans1downin humans1

2 studies
  1. Antihypertensive agents are linked with better blood pressure in humans.

    “Medication use contributed to the improvement in blood pressure, resting heart rate, and total cholesterol.”

    Humans8 yearsn = 3,528

    Cardiometabolic Risk Trajectory Among Older Americans: Findings From the Health and Retirement Study

    The journals of gerontology. Series A, Biological sciences and medical sciences

  2. Antihypertensive agents are linked with lower blood pressure in humans with and without stiffer arteries (-0.47 ± 0.20 mmHg/y; -0.47 ± 0.07 mmHg/y).

    “Antihypertensive treatment significantly affected the trajectory of BP in both participants with (-0.47 ± 0.20 mmHg/y, P = .02) and participants without stiffer arteries”

    Humanswith and without stiffer arteriesmedian follow-up of 6.8 years

    Impact of Stiffer Arteries on the Response to Antihypertensive Treatment: A Longitudinal Study of the SardiNIA Cohort

    Journal of the American Medical Directors Association

More on Blood pressure

Cardiovascular morbidity

downin humans2

2 studies
  1. Antihypertensive agents decrease cardiovascular morbidity in humans.

    “The available evidence in individuals aged> 80 years seems to indicate that antihypertensive treatment results in a reduction of cardiovascular morbidity and mortality.”

    Review

    Hypertension in older adults

    Hipertension y riesgo vascular

  2. Antihypertensive agents decrease cardiovascular morbidity in humans.

    “Medical treatment of hypertension reduces cardiovascular morbidity and mortality in the elderly”

    Review

    Management of hypertension in the elderly

    Nature reviews. Cardiology

More on Cardiovascular morbidity

Retinal arteriolar wall-to-lumen ratio

no changein humans1downin humans1

1 study
  1. Antihypertensive agents were not clearly linked with retinal arteriolar wall-to-lumen ratio in humans (multivariate analysis across drug regimens).

    “In multivariate analysis, hypertension drug regimen was not an independent predictor of any retinal anatomical indices.”

    Humansmultivariate analysis across drug regimensretinan = 1,000

    Effects of age, blood pressure and antihypertensive treatments on retinal arterioles remodeling assessed by adaptive optics

    Journal of hypertension

  2. Antihypertensive agents are linked with lower retinal arteriolar wall-to-lumen ratio in humans (short-term drug-induced blood pressure drop (-29.3 ± 17.3/-14.4 ± 10.0 mmHg)) (-6.0 ± 8.0%).

    “Short-term blood pressure drop (-29.3 ± 17.3/-14.4 ± 10.0 mmHg) induced a WLR decrease (-6.0 ± 8.0%) because of lumen dilatation (+4.4 ± 5.9%) without wall thickness changes.”

    Humansshort-term drug-induced blood pressure drop (-29.3 ± 17.3/-14.4 ± 10.0 mmHg)retina

    Effects of age, blood pressure and antihypertensive treatments on retinal arterioles remodeling assessed by adaptive optics

    Journal of hypertension

More on Retinal arteriolar wall-to-lumen ratio

Fall injuries

no changein humans1

1 study
  1. Antihypertensive agents were not clearly linked with fall injuries in humans (adjusted models).

    “antihypertensive use entered separately (yes, N= 1026/1273) had no association with fall injury”

    Humansadjusted models2 yearsn = 1,273

    Associations between fall risk increasing drugs (FRID) and fall & fall injuries in older Black and White men and women: the Health, Aging and Body Composition Study

    Archives of gerontology and geriatrics

Stroke recurrence

no changein humans1

1 study
  1. Antihypertensive agents showed no clear effect on stroke recurrence in humans.

    “During the follow-up, the incidence of adverse events such as stroke recurrence and major vascular events did not differ significantly between early and delayed treatment groups in any subgroup.”

    Human trial90 daysn = 4,802

    Initial systolic blood pressure, antihypertensive treatment timing and outcomes in acute ischemic stroke: a subgroup analysis of CATIS-2 trial

    Journal of hypertension

More on Stroke recurrence

Norepinephrine

downin humans1

1 study
  1. Antihypertensive agents decrease norepinephrine in humans (P<0.001).

    “significantly (P<0.001) reduced both MSNA and NE”

    Human trial3 months

    Lack of regional and whole body sympathetic normalization during antihypertensive drug treatment: a potential link for the residual risk

    High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension

More on Norepinephrine

Muscle sympathetic nerve traffic

downin humans1

1 study
  1. Antihypertensive agents decrease muscle sympathetic nerve traffic in humans (P<0.001).

    “significantly (P<0.001) reduced both MSNA and NE”

    Human trial3 months

    Lack of regional and whole body sympathetic normalization during antihypertensive drug treatment: a potential link for the residual risk

    High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension

More on Muscle sympathetic nerve traffic

Systolic blood pressure

downin humans1

1 study
  1. Antihypertensive agents decrease systolic blood pressure in humans (-4.1 mmHg (95% CI, -5.3 to -2.8; p < 0.001)).

    “Starting a new medication class post-enrollment resulted in an SBP drop of -4.1 mmHg (95% CI, -5.3 to -2.8; p < 0.001).”

    Human trial

    Estimating the Hawthorne Effect in Real-World Blood Pressure Control Trials: An Analysis of the BP Home Trial

    Journal of general internal medicine

More on Systolic blood pressure

All 47

What is antihypertensive agents linked with?

38

Studies link antihypertensive agents with 38 measures, among them mortality, dementia and cardiovascular disease.

Mortality

downin humans4HR 0.42–0.912

4 studies
  1. Antihypertensive agents are linked with a lower risk of mortality in humans (HR 0.912 (0.860–0.967)).

    “The overall survival rate was higher in A.H.T. users than non-users [HR: 0.912: 0.860, 0.967) P=0.002].”

    Humans

    Anti-Hypertensives Reduce the Rate of Alzheimer's Disease Progression: A Cohort Study Linked with Genetic and Neuropathological Analyses

    The journal of prevention of Alzheimer's disease

  2. Antihypertensive agents are linked with a lower risk of mortality in older hospitalized hypertensive patients at discharge.

    “adjusted multivariable logistic regression analysis showed that MT for hypertension at discharge was associated with lower risk of all-cause death”

    Humansin older hospitalized hypertensive patients at discharge

    Antihypertensive treatment changes and related clinical outcomes in older hospitalized patients

    European journal of clinical investigation

  3. Antihypertensive agents are linked with a lower risk of mortality in humans (very old adults hospitalized for acute HFpEF) (HR 0.42 [0.20-0.88], P = 0.02).

    “prescription for antihypertensive drugs at discharge was associated with a better long-term prognosis (all-cause mortality: HR: 0.42 [0.20-0.88], P = 0.02; re-hospitalization rate: HR: 0.56 [0.28-1.10], P = 0.09)”

    Humansvery old adults hospitalized for acute HFpEF1 yearn = 81

    Prognostic impact of systolic blood pressure in acute heart failure with preserved ejection fraction in older patients

    ESC heart failure

  4. Antihypertensive agents lower the risk of mortality in humans.

    “Antihypertensive treatment is shown to reduce the risk of cardiovascular events, stroke, chronic kidney disease, cognitive decline, and all-cause mortality.”

    Review

    Current concepts in the management of arterial hypertension in older and oldest-old adults

    Problems of ageing and longevity (Ukraine)

Dementia

downin humans4

4 studies
  1. Antihypertensive agents are linked with a lower risk of dementia in humans (24% (95% CI: 19%-28%) risk reduction for high exposure).

    “Exposure to treatment was inversely associated with the risk of dementia. Compared with patients with very low exposure, those with low, intermediate, and high exposure exhibited a 2% (95% CI: -4% to 7%), 12% (95% CI: 6%-17%), and 24% (95% CI: 19%-28%) risk reduction, respectively.”

    Humans

    Risk of Dementia During Antihypertensive Drug Therapy in the Elderly

    Journal of the American College of Cardiology

  2. Antihypertensive agents are linked with a lower risk of dementia in younger MCI patients.

    “Among younger MCI patients, those taking anti-hypertensive drugs faced a relatively low risk of dementia.”

    Humansin younger MCI patients

    Arrhythmia and other modifiable risk factors in incident dementia and MCI among elderly individuals with low educational levels in Taiwan

    Frontiers in aging neuroscience

  3. Antihypertensive agents lower the risk of dementia in humans.

    “Antihypertensive medications, particularly those that target the renin-angiotensin system, have promising neuroprotective benefits and somewhat lower the prevalence of dementia.”

    Review

    Hypertension as a Major Risk Factor in Alzheimer's Disease: Mechanisms, Interactions and Therapeutic Perspectives

    Clinical interventions in aging

  4. Antihypertensive agents lower the risk of dementia in humans.

    “antihypertensive agents appear to provide beneficial effects in reducing the risk dementia”

    Review

    Hypertension and Mild Cognitive Impairment: State-of-the-Art Review

    American journal of hypertension

More on Dementia

Cardiovascular disease

downin humans3

3 studies
  1. Antihypertensive agents are linked with a lower risk of cardiovascular disease in humans (SBP ≥140 mm Hg or DBP ≥90 mm Hg) (P for interaction <0.001 (SBP), P for interaction = 0.018 (DBP)).

    “Hypertension medication was associated with lower risk of primary composite outcomes in SBP ≥140 mm Hg (P for interaction for SBP <0.001) and diastolic blood pressure ≥90 mm Hg”

    HumansSBP ≥140 mm Hg or DBP ≥90 mm Hgmedian follow-up of 7.76 yearsn = 225,563

    Blood Pressure and Cardiovascular Disease in Older Patients With Diabetes: Retrospective Cohort Study

    Journal of the American Heart Association

  2. Antihypertensive agents lower the risk of cardiovascular disease in humans.

    “Antihypertensive treatment is shown to reduce the risk of cardiovascular events, stroke, chronic kidney disease, cognitive decline, and all-cause mortality.”

    Review

    Current concepts in the management of arterial hypertension in older and oldest-old adults

    Problems of ageing and longevity (Ukraine)

  3. Antihypertensive agents lower the risk of cardiovascular disease in healthy to mildly frail older adults.

    “the absolute benefit of hypertension control, including more intensive control, on cardiovascular events is greater in adults ≥ 80 than 60-79 years old.”

    Reviewin healthy to mildly frail older adults

    Managing Hypertension in Older Adults

    Current hypertension reports

More on Cardiovascular disease

Stroke

downin humans1downin silico1

2 studies
  1. Antihypertensive agents lower the risk of stroke in silico (0.96 million model-estimated strokes averted in 2019).

    “corresponding to an estimated 0.96 million model-estimated strokes averted in 2019.”

    In silico

    Global disparities in realized stroke prevention attributable to antihypertensive treatment: a population-level analysis of 198 countries, 1990-2019

    European journal of epidemiology

  2. Antihypertensive agents lower the risk of stroke in humans (more intensive hypertension treatment) (1.7 years (95%CI: 1.0-2.9) for ARR = 0.005).

    “We determined that 1.7 (95%CI: 1.0-2.9) years were required to prevent 1 stroke for 200 persons (ARR = 0.005) receiving more intensive hypertensive treatment.”

    Reviewmore intensive hypertension treatmentn = 38,779

    Time to benefit for stroke reduction after blood pressure treatment in older adults: A meta-analysis

    Journal of the American Geriatrics Society

More on Stroke

Mild cognitive impairment

downin humans2

2 studies
  1. Antihypertensive agents are linked with a lower risk of mild cognitive impairment in humans (time ratio: 1.04, 95% CI: 1.03-1.06).

    “antihypertensive use was associated with a modest prolongation of MCI-free survival overall (time ratio:1.04, 95% CI: 1.03-1.06)”

    Humans

    Integrative Multimodal Subtyping, Risk of Incident Mild Cognitive Impairment, and Differential Cardiometabolic Treatment Effects: A Prospective Cohort Study in the All of Us Research Program

    medRxiv : the preprint server for health sciencesPreprint

  2. Antihypertensive agents are linked with a lower risk of mild cognitive impairment in humans (hypertension).

    “Patients on antihypertensive therapy also had a lower prevalence of MCI.”

    Humanshypertensionn = 210

    Antihypertensive therapy is associated with improved visuospatial, executive, attention, abstraction, memory, and recall scores on the montreal cognitive assessment in geriatric hypertensive patients

    Cerebral circulation - cognition and behavior

More on Mild cognitive impairment

Falls

upin humans2

2 studies
  1. Antihypertensive agents are associated with falls in humans.

    “use of pain medications, antihypertensives, anti-seizure medications, and metformin was significantly more common among fallers than non-fallers.”

    Humansn = 459

    Medical Conditions and Medications Associated with Falls in Low-Income Community-Dwelling Older Adults

    The Senior care pharmacist

  2. Antihypertensive agents are associated with falls in humans (real-world pharmacovigilance reports) (12 positive signal drugs across 4 methods).

    “The FAERS database was used to confirm the potential connection between some antihypertensive drugs and fall adverse events through data mining algorithms.”

    Humansreal-world pharmacovigilance reportsn = 973,447

    Research on Beers Criteria and STOPP/START Criteria based on the FDA FAERS database

    European journal of clinical pharmacology

Alzheimer's disease

downin humans2RR 0.94

2 studies
  1. Antihypertensive agents lower the risk of Alzheimer's disease in humans (essential hypertension) (half as likely).

    “People with essential hypertension who regularly take prescribed BP medications are half as likely to develop AD as those who do not take them.”

    Reviewessential hypertension

    WNT/β-catenin Pathway: a Possible Link Between Hypertension and Alzheimer's Disease

    Current hypertension reports

  2. Antihypertensive agents are associated with Alzheimer's disease in humans (Adults with hypertension and normal cognition; comparison with non-antihypertensive users) (RR 0.94, 95% CI 0.90–0.99; p=0.01).

    “the use of antihypertensive agents is associated with a reduced risk of incident Alzheimer's disease (RR= 0.94, 95% CI 0.90-0.99; p=0.01).”

    ReviewAdults with hypertension and normal cognition; comparison with non-antihypertensive users

    Antihypertensive Agents and Incident Alzheimer's Disease: A Systematic Review and Meta-Analysis of Observational Studies

    The journal of prevention of Alzheimer's disease

More on Alzheimer's disease

Functional dependency or death

upin humans1OR 1.32

1 study
  1. Antihypertensive agents raise the risk of functional dependency or death in baseline SBP 160–179 mmHg subgroup (13.3% vs. 10.4%; OR 1.32, 95% CI 1.00–1.76).

    “At the 90-day follow-up, early antihypertensive treatment was associated with a higher risk of functional dependency or death compared with delayed treatment in the baseline SBP 160–179 mmHg subgroup (13.3% vs. 10.4%; OR 1.32, 95% CI 1.00–1.76).”

    Human trialin baseline SBP 160–179 mmHg subgroup90 daysn = 1,849

    Initial systolic blood pressure, antihypertensive treatment timing and outcomes in acute ischemic stroke: a subgroup analysis of CATIS-2 trial

    Journal of hypertension

  2. Antihypertensive agents raise the risk of functional dependency or death in humans (baseline SBP 160-179 mmHg) (13.3% vs. 10.4%; OR 1.32, 95% CI 1.00-1.76).

    “Among patients with baseline SBP 160-179 mmHg, early antihypertensive treatment was associated with increased risk of primary outcome compared to delayed treatment”

    Human trialbaseline SBP 160-179 mmHg90-dayn = 1,849

    Initial systolic blood pressure, antihypertensive treatment timing and outcomes in acute ischemic stroke: a subgroup analysis of CATIS-2 trial

    Journal of hypertension

Cardiovascular or cerebrovascular events

upin humans1HR 1.421

1 study
  1. Antihypertensive agents are associated with cardiovascular or cerebrovascular events in humans (Hypertension and type 2 diabetes mellitus; multivariable Cox model) (Adjusted HR 1.421 per additional agent, 95% CI 1.034–1.954; p = 0.030).

    “each additional antihypertensive agent was associated with an increased event hazard”

    HumansHypertension and type 2 diabetes mellitus; multivariable Cox modelEach additional antihypertensive agentUp to 16 yearsn = 78

    The Role of Circadian Blood Pressure Patterns in Long-Term Mortality in Hypertensive Type 2 Diabetes Mellitus: A Retrospective Cohort Study

    Biomedicines

Alzheimer's disease and related dementias

downin humans1

1 study
  1. Antihypertensive agents are linked with a lower risk of Alzheimer's disease and related dementias in humans (5% reduction, Effect 0.95 (95% CI 0.94-0.95)).

    “Overall, AHM use was associated with a 5% reduction in ADRD risk (Effect: 0.95; 95% CI: 0.94-0.95).”

    Humans

    Heterogeneity in the association between antihypertensive medications and Alzheimer's disease and related dementias risk: A multidimensional machine learning analysis to inform drug repurposing

    Journal of Alzheimer's disease : JAD

More on Alzheimer's disease and related dementias

All 38

What acts on antihypertensive agents?

1

Studies name 2017 acc/aha hypertension guideline as acting on antihypertensive agents.

2017 acc/aha hypertension guideline

no changein humans1upin humans1

1 study
  1. 2017 acc/aha hypertension guideline was not clearly linked with antihypertensive agents in humans (reclassified to Stage 1 hypertension) (77.3% to 78.4% (p=0.25)).

    “Antihypertensive use changed from 77.3% to 78.4% (p=0.25) among participants reclassified to Stage 1 hypertension”

    Humansreclassified to Stage 1 hypertensionn = 2,193

    The 2017 American College of Cardiology/American Heart Association Hypertension Guideline and Blood Pressure in Older Adults

    American journal of preventive medicine

  2. 2017 acc/aha hypertension guideline is linked with higher antihypertensive agents in humans (reclassified to Stage 2 hypertension) (from 78.3% to 81.4% (p<0.01)).

    “from 78.3% to 81.4% (p<0.01) among participants reclassified to Stage 2 hypertension”

    Humansreclassified to Stage 2 hypertensionn = 2,193

    The 2017 American College of Cardiology/American Heart Association Hypertension Guideline and Blood Pressure in Older Adults

    American journal of preventive medicine

More on 2017 acc/aha hypertension guideline

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Human studies report reduced cardiovascular disease and mortality with antihypertensive agents, with independent labs finding both changes again. Dementia associations include lower risk and no clear link, while a trial reports increased dependency or death at baseline systolic pressure of 160–179 mm Hg. Some papers declare company ties, and some authors work at companies.

  2. Summary rewritten as its findings changed.

    As it read before

    Antihypertensive agents reduce cardiovascular disease and mortality in human studies, with independent labs reporting these changes again. A human trial reports greater dependency or death in participants with baseline systolic pressure of 160–179 mm Hg, while observational links with dementia and falls vary. Papers include company-affiliated authors and declared company ties.

  3. Summary written from the findings.

Latest

Dec 2025: 10Jan 2026: 13Feb 2026: 11Mar 2026: 22Apr 2026: 4May 2026: 6Jun 2026: 7Jul 2026: 10Aug 2026: 5Sep 2026: 4Oct 2026: 1Nov 2026: 396 papers in 12 months
Hypertension

Frailty accelerates before and after hypertension diagnosis

Frailty scores rose 0.63 points per year before hypertension diagnosis and 1.09 points after, outpacing matched controls across eight years before and after diagnosis.Frailty scores rose 0.63 points per year before hypertension diagnosis and 1.09 points after, outpacing matched controls across eight years before and after diagnosis.

Cohort study of 21,418 peopleHypertension

See all 276 papers on antihypertensive agents